Abstract
In the past decade, enormous efforts have been devoted to understand the genetics and molecular pathogenesis of Alzheimers disease (AD), which has been transferred into extensive experimental approaches aimed at reversing disease progression. The trend in future AD therapy has been shifted from traditional anti-acetylcholinesterase treatment to multiple mechanisms-based therapy targeting amyloid plaques formation and amyloid peptides (Aβ)-mediated cytotoxicity, and neurofibrillary tangles generation. This review will cover current experimental studies with the focus on secretases-based drug development, immunotherapy, and anti-neurofibrillary tangles intervention. The outcome of these on-going studies may provide high hope that AD can be cured in the future.
Keywords: Experimental approach, Alzheimer's disease, secretase, amyloid plaque, neurofibrillary tangles, immunotherapy, small interfering molecule, gene therapy
Current Neuropharmacology
Title: Current Experimental Therapy for Alzheimers Disease
Volume: 5 Issue: 2
Author(s): Sheng Chen, Xiao-Jie Zhang, Liang Li and Wei-Dong Le
Affiliation:
Keywords: Experimental approach, Alzheimer's disease, secretase, amyloid plaque, neurofibrillary tangles, immunotherapy, small interfering molecule, gene therapy
Abstract: In the past decade, enormous efforts have been devoted to understand the genetics and molecular pathogenesis of Alzheimers disease (AD), which has been transferred into extensive experimental approaches aimed at reversing disease progression. The trend in future AD therapy has been shifted from traditional anti-acetylcholinesterase treatment to multiple mechanisms-based therapy targeting amyloid plaques formation and amyloid peptides (Aβ)-mediated cytotoxicity, and neurofibrillary tangles generation. This review will cover current experimental studies with the focus on secretases-based drug development, immunotherapy, and anti-neurofibrillary tangles intervention. The outcome of these on-going studies may provide high hope that AD can be cured in the future.
Export Options
About this article
Cite this article as:
Chen Sheng, Zhang Xiao-Jie, Li Liang and Le Wei-Dong, Current Experimental Therapy for Alzheimers Disease, Current Neuropharmacology 2007; 5 (2) . https://dx.doi.org/10.2174/157015907780866901
DOI https://dx.doi.org/10.2174/157015907780866901 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Tumor Specific Novel Taxoid-Monoclonal Antibody Conjugates
Current Medicinal Chemistry Modulating the Amyloidogenesis of α-Synuclein
Current Neuropharmacology Therapeutic microRNA Delivery Strategies with Special Emphasis on Cancer Therapy and Tumorigenesis: Current Trends and Future Challenges
Current Drug Metabolism Biomarkers of Angiogenesis and their Role in Patient Selection for Antiangiogenic Therapy
Current Angiogenesis (Discontinued) Tetracyclines and Prion Infectivity
Infectious Disorders - Drug Targets Trafficking and Signaling of G Protein-Coupled Receptors in the Nervous System: Implications for Disease and Therapy
CNS & Neurological Disorders - Drug Targets Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets Function of miRNA in Controlling Drug Resistance of Human Cancers
Current Drug Targets Combining Angiogenesis Inhibitors with Radiation: Advances and Challenges in Cancer Treatment
Current Pharmaceutical Design Coenzyme Q10 in Neuromuscular and Neurodegenerative Disorders
Current Drug Targets The Role of Tregs in Cancer: Foxp3 as a Putative Target for Therapy
Current Signal Transduction Therapy Emerging Roles for Modulation of microRNA Signatures in Cancer Chemoprevention
Current Cancer Drug Targets The Evaluation of Animal Models in the Development of Anticancer Agents: From Preclinical to Clinical Tests
Current Cancer Drug Targets The Path from Anti Parkinson Drug Selegiline and Rasagiline to Multifunctional Neuroprotective Anti Alzheimer Drugs Ladostigil and M30
Current Alzheimer Research Transcriptional Regulation of the p53 Tumor Suppressor Gene: A Potential Target for Cancer Therapeutics?
Recent Patents on DNA & Gene Sequences Anionic Host Defence Peptides from the Plant Kingdom: Their Anticancer Activity and Mechanisms of Action
Protein & Peptide Letters Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment
Current Pharmaceutical Design PET Studies on P-Glycoprotein Function in the Blood-Brain Barrier: How it Affects Uptake and Binding of Drugs within the CNS
Current Pharmaceutical Design Acetylcholinesterase Inhibitors and Drugs Acting on Muscarinic Receptors- Potential Crosstalk of Cholinergic Mechanisms During Pharmacological Treatment
Current Neuropharmacology Melatonin-mitochondria Interplay in Health and Disease
Current Topics in Medicinal Chemistry